Abstract: Background: Hemangioblastomas represent rare benign tumors of the central nervous system. In the case of metastatic spread and limited surgical options, systemic treatment may be considered. However there is no standard of care beyond surgery. Case Report: We report the cases of 2 patients with progressive multilocular hemangioblastomas, who showed clinical benefit and radiological stabilization of tumor growth after treatment with bevacizumab, an antibody against the vascular endothelial growth factor. Conclusion: Our case reports suggest activity of bevacizumab in hemangioblastomas after failure of standard therapeutic options.

DOI: https://doi.org/10.1159/000341075

Original publication:
DOI: https://doi.org/10.1159/000341075
Antiangiogenic treatment for multiple CNS hemangioblastomas

Anti-angiogene Therapie bei multiplen Hämangioblastomen im ZNS

**Short title:** Bevacizumab for multiple hemangioblastomas

**Kurztitel:** Bevacizumab bei multiplen Hämangioblastomen
Antiangiogenic treatment for multiple CNS hemangioblastomas
Anti-angiogene Therapie bei multiplen Hämangioblastomen im ZNS

Christian Riklin¹*, Katharina Seystahl², Silvia Hofer³, Caroline Happold², Ralph Winterhalder¹, Michael Weller²

¹Division of Medical Oncology, Cantonal Hospital of Lucerne, Lucerne, Switzerland,
²Department of Neurology, University Hospital Zurich, Zurich Switzerland,
³Department of Medical Oncology, University Hospital Zurich, Zurich, Switzerland
Correspondence to: Christian Riklin, MD, Division of Medical Oncology, Cantonal Hospital of Lucerne, CH – 6000 Lucerne 16, Switzerland, phone +41 41 205 58 73, fax +41 41 205 58 62, christian.riklin@ksl.ch

Keywords: hemangioblastoma, bevacizumab, von Hippel-Lindau syndrome, antiangiogenesis
Schlüsselwörter: Hämangioblastom, Bevacizumab, von Hippel-Lindau-Syndrom, Antiangiogenese
Summary
Background: Hemangioblastomas represent rare benign tumors of the central nervous system. In case of multilocular spread disease and limited surgical options, systemic treatment may be considered. However, there is no standard of care beyond surgery.
Case report: We report 2 patients with progressive multilocular hemangioblastomas who showed clinical benefit and radiological stabilization of tumor growth after treatment with bevacizumab, an antibody against vascular endothelial growth factor (Avastin®, Roche).
Conclusion: Our case reports suggest activity of bevacizumab in hemangioblastomas after failure of standard therapeutic options.

Zusammenfassung
Kasuistik: Wir berichten von zwei Patienten mit progredienten multiplen Hämangioblastomen, die unter einer Behandlung mit Bevacizumab, einem Antikörper gegen den vaskulären endothelialen Wachstumsfaktor (Avastin®, Roche) klinisch profitierten und bildgebend eine Stabilisierung der Erkrankung zeigten.
Schlussfolgerung: Unsere Fallberichte zeigen eine mögliche Wirksamkeit von Bevacizumab bei Hämangioblastomen, wenn die Optionen der Standardtherapie ausgeschöpft sind.
Introduction

Hemangioblastomas are rare benign tumors of the central nervous system (CNS) accounting for about 2% of all intracranial tumors [1]. Surgical resection is the standard of care. However, multiple cerebral hemangioblastomas may require systemic treatment. We report 2 patients with progressive multilocular hemangioblastoma who were treated with the vascular endothelial growth factor (VEGF) antibody bevacizumab (Avastin®, Roche). The experimental treatment was administered as a compassionate use of the drug after written informed consent of the patient or, in case 1, of the patient’s wife as the responsible representative.

Case 1

A 53-year-old man was admitted in Lucerne in July 2010 with seizures, somnolence and confusion. The clinical deterioration had developed over the course of three months. Twelve years earlier he had been diagnosed with cerebellar hemangioblastoma which was completely resected. MRI scan revealed multiple lesions in the brain, the brain stem and the spine (fig. 1A) with prominent perifocal edema (fig. 1B). A large frontotemporal biopsy confirmed recurrent hemangioblastoma WHO grade 1. A mutation of the von Hippel-Lindau (VHL) gene was ruled out. The patient received antiepileptic treatment with carbamazepine and intravenous dexamethasone (32 mg per day) over the course of 14 days without any improvement of his clinical condition. In the absence of evidence-based systemic therapy, we started antiangiogenic treatment with bevacizumab (10 mg/kg). Eight days after the first infusion the patient’s general condition had greatly improved. Treatment was continued at 14 days intervals whereas dexamethasone was tapered and finally stopped. MRI showed stable disease and reduction of the edema (fig. 1C and D). After a rehabilitation program the patient was discharged in October 2010. He has gained autonomy in activities of daily living with a Karnofsky performance score of 80 with occasional seizures. In conclusion, the clinical observation of the rapid decline before the start of bevacizumab and remarkable and prompt improvement of the patient’s condition after the start of bevacizumab together with a stable course of the disease hereafter was suggestive of activity of bevacizumab. The durable reduction of edema despite withdrawal of steroids confirmed the activity of bevacizumab. In April 2011, however, bevacizumab was stopped because of
clinical and radiological progression (fig. 1E). In July 2011 the patient is still alive, but needs help in all activities of daily living.

Case 2
A 67-year-old man had a solitary left cerebellar capillary hemangioblastoma WHO grade 1 resected in August 1994. Since July 2009 he developed a progressive gait disorder which led to the diagnosis of local tumor recurrence. He underwent repeat gross total resection in December 2009 in Zurich. No lesions suggestive of VHL disease were identified and no germline mutations were found upon analysis of exons 1-3 of the VHL gene. Cerebrospinal fluid protein was elevated and spinal MRI showed multiple contrast-enhancing lesions; cranial MRI showed mild leptomeningeal contrast enhancement (fig. 2A). The patient received no further treatment and the spinal lesions progressed over months (fig. 2B). Proof of multilocular disease along the spinal axis was obtained by biopsy of one spinal lesion in July 2010. The spinal manifestation of the disease was reflected by the clinical pattern of the mainly sensory gait disturbance involving pathological sensory evoked potentials, severe pallhypesthesia and positive Romberg’s sign. The gait disorder further progressed, leading to severe disability with inability to walk a few meters without support. Since surgery, radiation and chemotherapy were not considered promising therapeutic options, sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, was started in September 2010, based on the assumption that VEGF receptor signal transduction was required for tumor cell proliferation. After one week of sunitinib treatment (50 mg/d), the patient developed headaches and episodes of impaired consciousness caused by CSF flow obstruction triggered by hemorrhage observed in the lateral ventricles on CT scan, and confirmed by lumbar puncture. Sunitinib was stopped since an association with the bleeding could not be excluded. A ventriculoperitoneal shunt was placed and the patient recovered slowly over the course of several weeks. Still, the follow-up craniospinal MRI in December 2010 showed further progression of both intraspinal tumor manifestations and contrast enhancement of the cerebral leptomeninges (fig. 2C). After the resolution of the bleeding was confirmed by craniospinal MRI and CSF analysis, the patient was started on bevacizumab (10 mg/kg, every 2 weeks). Gait improved slowly and almost no signs of ataxia were left by March 2011, after 4 applications of bevacizumab. The MRI was virtually unchanged at this time (data not shown). Bevacizumab was
continued and the MRI after 4 months of treatment with bevacizumab (5/2011) showed stable disease again (fig. 2D). To date, the patient walks 4 kilometers every day without any support; his Karnofsky performance status improved from 70% to 90%.

**Discussion**

Benign hemangioblastomas of the central nervous system may occur sporadically, but are mostly seen in association with VHL disease. Patients with VHL disease usually have less severe neurological symptoms and present at an earlier age than patients with sporadic lesions [2, 3]. Microsurgical resection is the treatment of choice. For unresectable symptomatic tumors, stereotactic radiosurgery may be an alternative approach with less durable local control [4]. Despite complete excision, de novo tumors can develop years after the initial diagnosis [5]. Hemangioblastomas develop from neoplastic stromal cells producing VEGF [6-8]. By consequence, hemangioblastomas present histologically with a dense vascular network. Therefore, antiangiogenic treatment seems logical when complete microsurgical resection is impossible. Sunitinib is one of the most frequently used antiangiogenic agent and currently under investigation in a phase II study (ClinicalTrials.gov Identifier: NCT00589784). So far, no experience with intravenous bevacizumab has been published; however, intravitreal bevacizumab has been described in patients with VHL-associated retinal hemangioblastomas [9, 10]. To date one open phase 0 study investigates bevacizumab in hemangioblastomas (ClinicalTrials.gov Identifier: NCT01015300). The two patients described here experienced an impressive and long-lasting clinical benefit. They demonstrated radiological stabilisation of symptomatic multifocal hemangioblastomas in the brain and spine with bevacizumab. The failure to induce objective remission suggests that VEGF is not a survival factor for the tumor cells whereas the induction of stable disease indicates that VEGF may be a growth factor in this disease. The clinical benefit is difficult to explain, but may be caused by a reduction of perfusion and edema and possibly improved perfusion of adjacent brain parenchyma. Possible mechanisms are the known decreases in capillary density, microvascular flow and blood vessel permeability in response to bevacizumab [11, 12]. We conclude that bevacizumab merits further investigation in this condition.
Authors’ disclosures of potential conflicts of interest
MW has received research support and honoraria for advisory board participation and lecturing from Roche (Basel, Switzerland), the manufacturer of bevacizumab (Avastin®). The other authors declare no potential conflicts of interest.

Figure legends

Figure 1
Cranial MRI of patient 1, showing contrast-enhancing lesions (A, 7/2010) and cerebral edema (B, 7/2010), with stable disease after a period of 6 months (C, 1/2011) and reduction of cerebral edema (D, 1/2011). Progression occurred after 9 months of treatment (E, 4/2011) (Department of Diagnostic Radiology and Nuclear Medicine, Cantonal Hospital of Lucerne, Lucerne, Switzerland).

Figure 2
Spinal and cranial MRI of patient 2, showing mild leptomeningeal contrast-enhancing lesions (A, 12/2009) which progressed over a time period of 9 months (B, 8/2010). Further progression occurred after 4 additional months including one week treatment with sunitinib (C,12/2010). In contrast, contrast-enhancing lesions have been unchanged after 4 months of treatment with bevacizumab (D, 5/2011) (MRI scans: courtesy of Radiology Institute Lindberg, Winterthur, Switzerland).

Consent
Written informed consent was obtained from the patients for publication of this report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Authors’ contributions
CR was responsible for conception and writing of the article and for patient care; KS was responsible for writing of the article and for patient care. CH was responsible for patient care. SH, RW and MW supervised the article and patient care.

References:


